Bliss Aesthetics ('Bliss') Secures $17.5 Million Seed Round to Launch AI-Powered Platform Connecting Patients with Board-Certified Plastic Surgeons
NEW YORK and TEL AVIV, Israel , April 10, 2025 /PRNewswire/ -- Bliss Aesthetics ('Bliss'), an AI-driven platform for cosmetic enhancement, announced its $17.5 million seed funding round to grow the platform amid a rapidly evolving cosmetic procedure market estimated to climb to $200 billion in revenue within 10 years. Shine Capital led the financing, followed by Synchrony Ventures, Sheva Ventures, Point72 Ventures, and Cerca Partners.
25% of Americans have undergone a medical aesthetic procedure, and this is expected to skyrocket by 55% among American men. Using GenAI, Stable Diffusion, and computer vision models, Bliss' platform meets a pressing need by allowing patients to realistically visualize their cosmetic enhancements and select a board-certified physician who meets their expectations. The platform also provides information about potential financing partners to create a seamless experience from start to finish. Further, the platform improves patient engagement from 40% to 80%, allowing doctors to focus on their craft and scale their businesses effortlessly.
'This funding will give us the ability to harness the momentum we are experiencing, building on the 500% growth of our provider base in our patient-to-physician app since our launch while expanding to five new states across the country,' said Gal Yosef, Bliss' Co-Founder and CEO. 'By combining intelligent matchmaking with AI tools, we equip patients to make informed, confident, and financially savvy decisions and give doctors the ability to deliver better outcomes to more patients with less administrative burden.'
Celebrity doctor and board-certified plastic surgeon Dr. Michael Salzhauer, also known as Dr. Miami, who co-founded the platform and serves as Chief Medical Officer, added, 'Through working firsthand in the industry, I've seen the need for a seamless consumer platform like Bliss. For physicians, the next-generation platform streamlines patient management and positions surgeons to deliver more precise patient outcomes and improve satisfaction. It's simply a game changer for cosmetic and plastic surgery.'
'From the moment we met Gal and the Bliss team, we recognized that they had identified a massive market need - for physicians and their patients,' said Mo Koyfman, Founder and General Partner at Shine Capital. 'We love investing in areas undergoing a radical shift in consumer perceptions and behavior. Cosmetic surgery is an area driven by demographics, and building technology tools to serve patients and providers helps the market develop while ensuring the highest-quality experience. Gal and the Bliss team are poised to create a category-defining technology platform and marketplace in this highly personal and massively growing space.'
'Synchrony knows from experience with our own CareCredit network of providers that transparency and access to information is key in the health and wellness industry,' said Maran Nalluswami, EVP and Chief Strategy and Business Development Officer at Synchrony. 'This investment is a natural fit for us to support digital innovations that connect patients with knowledge and the ability to finance the care they want and need.'
The Bliss Aesthetics platform is available to patients across Florida, Texas, Illinois, Arizona, Michigan, and North Carolina.
About Bliss Aesthetics
Bliss is the first system of intelligence for cosmetic enhancement. By combining an AI-powered decision engine with intelligent matchmaking and 24/7 customer assistance, Bliss equips patients to make informed, confident decisions and gives surgeons the tools to serve their patients better while having more time to focus on performing procedures. To learn more, visit https://www.bliss.me/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
21 minutes ago
- Chicago Tribune
Robert F. Kennedy Jr. and other Trump officials embrace psychedelics after FDA setback
WASHINGTON — For decades, proponents of psychedelic drugs have come to Washington with a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for Americans grappling with depression, trauma and other hard-to-treat conditions. A presidential administration finally seems to agree. 'This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,' Health Secretary Robert F. Kennedy Jr. recently told members of Congress. His suggested timeline for green-lighting psychedelic therapy surprised even the most bullish supporters of the drugs. And it comes as psychedelics are making inroads in deep red states like Texas, where former Trump cabinet secretary and ex-governor Rick Perry has thrown his full support behind the effort. The administration's embrace of psychedelics has sparked both excitement as well as concern from those in the field, who worry the drugs might be discredited if they appear to be rushed onto the market or are too closely linked with Kennedy, who is known for controversial views on vaccines, antidepressants and fluoride. 'I'm quite optimistic,' says Rick Doblin, whose organization has pursued the medical use of MDMA (or ecstasy) since the 1980s. 'But I'm also worried that the message the public might get is 'Well, RFK likes psychedelics and now it's approved.'' Under President Joe Biden, the FDA rejected MDMA as a treatment for post-traumatic stress disorder, citing flawed data and questionable research. Regulators called for a new study, likely taking several years. It was a major setback for Doblin and other advocates hoping to see the first U.S. approval of a psychedelic for medical use. But the agency appears ready to reconsider. FDA chief Marty Makary, who reports to Kennedy, has called the evaluation of MDMA and other psychedelics 'a top priority,' announcing a slate of initiatives that could be used to accelerate their approval. One new program promises to expedite drugs that serve 'the health interests of Americans,' by slashing their review time from six months or more to as little as one month. Makary has also suggested greater flexibility on requirements for certain drugs, potentially waiving rigorous controlled studies that compare patients to a placebo group. That approach, considered essential for high-quality research, has long been a stumbling point for psychedelic studies, in which patients can almost always correctly guess whether they've received the drug or a dummy pill. The U.S. Department of Health and Human Services and FDA also recently hired several new staffers with ties to the psychedelic movement. 'These are all very promising signs that the administration is aware of the potential of psychedelics and is trying to make overtures that they're ready to approve them,' said Greg Ferenstein, a fellow at the libertarian Reason Foundation, who also consults for psychedelic companies. 'We didn't hear anything about that in the Biden administration' A spokesperson for HHS did not respond to a request for comment. As a presidential candidate, Kennedy discussed how his son and several close friends benefited from using psychedelics to deal with grief and other issues. A number of veterans lobbying for psychedelic access have already met with Trump's Secretary of Veterans Affairs, Doug Collins. 'What we're seeing so far is positive,' Collins told House lawmakers in May. But some experts worry the hope and hype surrounding psychedelics has gotten ahead of the science. Philip Corlett, a psychiatric researcher at Yale University, says bypassing rigorous clinical trials could set back the field and jeopardize patients. 'If RFK and the new administration are serious about this work, there are things they could do to shepherd it into reality by meeting the benchmarks of medical science,' Corlett said. 'I just don't think that's going to happen.' As officials in Washington weigh the future of psychedelics, some states are moving ahead with their own projects in hopes of nudging the federal government. Oregon and Colorado have legalized psychedelic therapy. And last month, Texas approved $50 million to study ibogaine, a potent psychedelic made from a shrub that's native to West Africa, as a treatment for opioid addiction, PTSD and other conditions. The research grant — the largest of its kind by any government — passed with support from the state's former GOP governor, Perry, and combat veterans, some who have traveled to clinics in Mexico that offer ibogaine. Ibogaine is on the U.S. government's ultra-restrictive list of illegal, Schedule 1 drugs, which also includes heroin. So advocates in Texas are hoping to build a national movement to ease restrictions on researching its use. 'Governmental systems move slowly and inefficiently,' said Bryan Hubbard of Americans for Ibogaine, a group formed with Perry. 'Sometimes you find yourself constrained in terms of the progress you can make from within.' Ibogaine is unique among psychedelics in both its purported benefits and risks. Small studies and anecdotal reports suggest the drug may be able to dramatically ease addiction and trauma. It was sold for medical use in France for several decades starting in the 1930s, but the drug can also cause dangerous irregular heart rhythms, which can be fatal if left untreated. Some veterans who have taken the drug say the risks can be managed and ibogaine's healing properties go far beyond antidepressants, mood stabilizers, counseling and other standard treatments. Marcus Capone struggled with anger, insomnia and mood swings after 13 years as a Navy Seal. In 2017, at the urging of his wife Amber, he agreed to try ibogaine as a last resort. He described his first ibogaine session as 'a complete purge of everything.' 'But afterward I felt the weight just completely off my shoulders,' he said. 'No more anxiety, no more depression, life made sense all of a sudden.' A nonprofit founded by the Capones, Veterans Exploring Treatment Solutions, or VETS, has helped over 1,000 veterans travel abroad to receive ibogaine and other psychedelics. But federal scientists have looked at the drug before — three decades ago, when the National Institute on Drug Abuse funded preliminary studies on using it as an addiction treatment. The research was discontinued after it identified 'cardiovascular toxicity.' 'It would be dead in the water,' in terms of winning FDA approval, longtime NIDA director Nora Volkow said. But Volkow said her agency remains interested in psychedelics, including ibogaine, and is funding an American drugmaker that's working to develop a safer, synthetic version of the drug. 'I am very intrigued by their pharmacological properties and how they are influencing the brain,' Volkow said. 'But you also have to be very mindful not to fall into the hype and to be objective and rigorous in evaluating them.'
Newsweek
22 minutes ago
- Newsweek
Map Shows Countries That Don't Allow Dual Citizenship
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Data mapped by Newsweek shows which countries do not allow dual citizenship. Why It Matters A recent Harris Poll survey revealed that 42 percent of U.S. adults have thought about or intend to move abroad to enhance their lifestyle or financial well-being. This figure climbs to 63 percent among Gen Z adults and 52 percent among millennials. What To Know According to Henley & Partners—a U.K.-based investment migration consultancy—at least 39 countries do not permit dual citizenship. In Africa, these include Botswana, Cameroon, Democratic Republic of Congo, Equatorial Guinea, Eritrea, Ethiopia, Eswatini, Guinea, Libya, Mauritania, Senegal, Tanzania, and Congo. In the Americas, Cuba and Suriname do not allow dual citizenship; in Europe, these include Andorra, Estonia, Monaco, and San Marino. As for Asia, Henley & Partners says countries that prohibit dual citizenship include: Azerbaijan Bhutan Brunei China India Indonesia Iran Japan Kazakhstan Kuwait Laos Malaysia Myanmar Nepal North Korea Oman Qatar Saudi Arabia Singapore Uzbekistan Countries that ban dual citizenship typically do so to preserve national identity, ensure loyalty, and avoid legal complications, Henley & Partners said. Key reasons include concerns over divided allegiance, potential security risks (like military conflicts or espionage), legal complexities related to taxation and rights, and fears that dual nationality may dilute cultural or political cohesion. Notable examples include China, India, and Singapore. China fully bans dual citizenship, citing the importance of loyalty and safeguarding national unity. India disallows it to maintain legal and administrative clarity, offering Overseas Citizenship of India (OCI) status instead, which grants limited privileges without full citizenship. Singapore upholds a firm one-citizenship rule, stressing national allegiance and requiring proof of renunciation of other citizenships before granting naturalization, the firm said. What People Are Saying Tim Osiecki, director of thought leadership and trends at The Harris Poll, previously told Newsweek: "For most of modern history, the American Dream was rooted in one place: America. But that's shifting," "While dual citizenship used to be reserved for retirees, the wealthy, or those with strong family ties abroad, it's now a growing goal for middle-class Americans who want more control over their future," he said. "It marks a real mindset shift—less about pledging allegiance to one nation, more about staying agile in a world that feels increasingly unstable." What Happens Next "This isn't about a mass migration overnight—but we are at a tipping point," Osiecki said previously. "One in five younger Americans say they're seriously considering moving abroad, and that kind of intent matters. So, while it may not be an exodus yet, it's certainly a movement, and it speaks volumes about how people are feeling about life in the U.S. right now," he said. "The American Dream may not be ending—it could simply be relocating."
The Verge
22 minutes ago
- The Verge
Scale AI lays off 200 employees: ‘We ramped up our GenAI capacity too quickly'
Scale AI, the AI industry's chief data dealer, will lay off 14 percent of its workforce, or about 200 employees, just one month after Meta took a multibillion-dollar stake in the company and hired its CEO and other staff. The layoffs include 500 of its global contractors, Scale spokesperson Joe Osborne told The Verge, adding that it's all part of a broader restructuring as the company commits to streamlining its data business. Bloomberg was the first to report on the news of the layoffs. Scale AI is an AI data labeling company. It uses human workers — often sourced from outside the US — to annotate the data used by companies like Google, OpenAI, and Anthropic to train their AI models. The news comes amid a major shake-up in the AI industry as mergers and acquisitions, quasi acqui-hires, and defections from one startup to another run rampant. On July 11th, The Verge was first to report that OpenAI's deal with Windsurf was off and that Google would be hiring Windsurf CEO Varun Mohan, cofounder Douglas Chen, and some of Windsurf's R&D employees. Last month, Meta paid $14.3 billion for a 49 percent stake in Scale AI and also launched a superintelligence lab helmed by the company's former CEO, Alexandr Wang. Meta has since started to build out the lab with high-level staff from its rivals. Jason Droege, CEO of Scale AI, sent an email to all Scale employees today, which was viewed by The Verge. Droege said he plans to restructure several parts of Scale's generative AI business and organize it from 16 pods to 'the five most impactful': code, languages, experts, experimental, and audio. The company will also reorganize its go-to-market team into a single 'demand generation' team that will have four pods, each covering a specific set of customers. 'The reasons for these changes are straightforward: we ramped up our GenAI capacity too quickly over the past year,' Droege wrote. 'While that felt like the right decision at the time, it's clear this approach created inefficiencies and redundancies. We created too many layers, excessive bureaucracy, and unhelpful confusion about the team's mission. Shifts in market demand also required us to re-examine our plans and refine our approach.' Droege said that he believes the changes to the company will make it more able to adapt to market shifts, serve existing customers, and win back customers that have 'slowed down' work with Scale. He also said that the company would deprioritize generative AI projects with less growth potential. 'We remain a well-resourced, well-funded company,' he wrote. Scale's generative AI business unit will have an all-hands meeting tomorrow, followed by a company-wide meeting on July 18th. Osborne said that Scale plans to increase investment and hire hundreds of new employees in areas like enterprise, public sector, and international public sector, in the second half of 2025 and that severance has been paid out to impacted roles. 'We're streamlining our data business to help us move faster and deliver even better data solutions to our GenAI customers,' he said.
